You are here

Y-mAbs

FDA Action Alert: Spectrum, ImmunoGen, Scynexis and Y-mAbs

BioSpace

Mon, 11/21/22 - 10:06 am

Spectrum Pharmaceuticals

mirevtuximab soravtansine

Several weeks after getting hit with an RTF, Y-mAbs lands approval for its other neuroblastoma candidate

Endpoints

Mon, 11/30/20 - 10:36 am

Go or no go? Big decisions loom for Bristol and Sanofi

EP Vantage

Fri, 10/30/20 - 10:12 am

Bristol-Myers Squibb

FDA hands Y-mAbs refusal to file letter in one of its pediatric neuroblastoma programs

Endpoints

Tue, 10/6/20 - 10:54 am

Y-mAbs ramps up head count in post-IPO hiring spree

Fierce Biotech

Thu, 08/15/19 - 11:33 pm

Y-mAbs raises $96M in upsized IPO

BioCentury

Fri, 09/21/18 - 12:12 am

Y-mAbs Plans IPO to Advance Two Pediatric Cancer Drugs to the FDA

Xconomy

Tue, 08/28/18 - 10:20 am

pediatric cancer